Skip to main content
KBS_Icon_questionmark link-ico
Professor Andre Cobb
Dr Andre Cobb

Professor Andre Cobb

  • Academics

Professor of Organic Chemistry

Academic Planning Lead . Organic and Biological Chemistry Section Lead. Advanced Topics in Synthesis Module Lead.

Research subject areas

  • Chemistry

Contact details

Biography

Professor Andre Cobb is a Professor of Organic Chemistry in the Department of Chemistry, King's College London. Andre obtained his first degree in Chemistry from King’s College London before undertaking doctoral work on asymmetric organozinc chemistry at UCL with Professor Charles Marson. After this he moved to the University of Cambridge to conduct postdoctoral research firstly with Professor Florian Hollfelder on the development of synthetic enzymes and then with Professor Steven V Ley CBE FRS where he developed asymmetric organocatalytic methodologies. He then went on to his first independent academic position at the University of Reading where his work won him a faculty research prize, as well as a Thieme Chemistry Journals award. He was promoted to Senior Lecturer in 2012, and then moved to the Department of Chemistry - back at his alma mater King’s College London in October 2016. Andre is also an Associate Editor for the Royal Society of Chemistry’s New Journal of Chemistry.

Research Interests

  • Asymmetric synthesis
  • Organocatalysis
  • Foldamer design and synthesis,
  • Medicinal chemistry
  • Total synthesis

Teaching

  • Organic Chemistry 3
  • Advanced Topics in Synthesis and Reactivity
  • UG Research Methods Literature Review
  • MSci Chemistry Frontiers
  • MSci Research Project & Dissertation
  • MRes Expanding the Frontiers of Chemistry
  • MRes Research Project in Interdisciplinary Chemistry 

Research profile

For more information on Dr Cobb's research please his Research Portal page.

The Cobb Group

Postgraduate Researchers

The Cobb Group has been involved in the development of asymmetric methodologies towards biologically inspired molecules since 2005. They have pioneered the synthesis of unnatural amino acids, mono and diterpenes (such as the cannabinoids), steroids, alkaloids and nucleoside frameworks – generally all using organocatalytic approaches. They have also applied many of these targets towards purposes such as the design of antivirals, anticonvulsants, lipids, and cardiac medications. In particular, they have used unnatural amino acids within unnatural peptides with highly defined secondary structures (so-called foldamers) that themselves can be applied to catalysis or peptidomimetics (with an example target being an enzyme of SARS-CoV-2). The Cobb Group has also developed a range of bifunctional probes for the detection of protein movement in real time. They also collaborate with many other groups both national and international. The Cobb Group is very well-equipped for synthetic methodology, with a chiral phase HPLC, an automated chromatography unit, ozonizer, cryocooler, and polarimeter in addition to the usual synthetic organic chemistry furnishings (stirrer hotplates, rotavaps etc). Funding has been obtained from EPSRC, BBSRC, MRC, CR-UK, the Leverhulme Trust, the Royal Society and Industry (e.g. Syngenta, GW Pharmaceuticals) amongst others.

Visit the Cobb Group website to find out more.